These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38290666)

  • 1. Editorial Comment on " Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment".
    Van Kuiken ME
    Urology; 2024 Apr; 186():130. PubMed ID: 38290666
    [No Abstract]   [Full Text] [Related]  

  • 2. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
    Chancellor MB; Lucioni A; Staskin D
    Urology; 2024 Apr; 186():123-129. PubMed ID: 38296001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O; Uchida E; Higo N; Minami H; Kobayashi S; Sato H;
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence.
    Cartwright R; Srikrishna S; Cardozo L; Robinson D
    BJU Int; 2011 Jan; 107(1):70-6. PubMed ID: 20626389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder.
    Herschorn S; Vicente C; Piwko C
    J Med Econ; 2010; 13(3):508-15. PubMed ID: 20690893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better management of patients with overactive bladder with antimuscarinics?
    MacDiarmid S
    Int J Clin Pract; 2008 Jan; 62(1):3-4. PubMed ID: 18173809
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
    Wagg A; Dale M; Tretter R; Stow B; Compion G
    Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive function assessment in elderly patients with overactive bladder treated with transdermal oxybutynin.
    Müller-Arteaga C; Batista-Miranda JE; Zubiaur Libano C; El Khoury Moreno R; Morales Solchaga G; Casas Nebra J; Leva Vallejo M; Gonzalez Garcia O; Errando-Smet C; Arlandis-Guzman S
    Actas Urol Esp (Engl Ed); 2019 Apr; 43(3):143-150. PubMed ID: 30470585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin gel for the treatment of overactive bladder.
    Gomelsky A; Dmochowski RR
    Expert Opin Pharmacother; 2012 Jun; 13(9):1337-43. PubMed ID: 22607010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Post-hoc analysis of a phase III randomized clinical trial.
    Yokoyama O; Yamaguchi A; Yoshida M; Yamanishi T; Ishizuka O; Seki N; Takahashi S; Yamaguchi O; Higo N; Minami H; Masegi Y
    Int J Urol; 2015 Jul; 22(7):684-8. PubMed ID: 25782032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [High patient satisfaction with the transdermal system].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):27. PubMed ID: 23646401
    [No Abstract]   [Full Text] [Related]  

  • 20. Does oxybutynin hydrochloride cause arrhythmia in children with bladder dysfunction?
    Ciftci I; Arslan D; Peru H; Cimen D; Oran B; Gunduz M
    Med Arch; 2013; 67(3):202-4. PubMed ID: 23848044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.